MX2016011674A - Combinacion que comprende un inhibidor de btk y un inhibidor de akt. - Google Patents
Combinacion que comprende un inhibidor de btk y un inhibidor de akt.Info
- Publication number
- MX2016011674A MX2016011674A MX2016011674A MX2016011674A MX2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A MX 2016011674 A MX2016011674 A MX 2016011674A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- akt
- btk
- combination
- chloro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una combinación novedosa que comprende un inhibidor de BTK, por ejemplo 1-[(3R)-3-[4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pir imidin-1-il] piperidin-1-il]prop-2-en-1-ona, o una sal farmacéuticamente aceptable del mismo, y un inhibidor de AKT, por ejemplo: N-{(1S)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-( 4-cloro-1-metil-1H-pirazol-5-il)-2-tiofencarboxamida, o una sal farmacéuticamente aceptable del mismo, y agentes antineoplásicos adicionales opcionales; composiciones farmacéuticas que comprenden los mismos y métodos de uso de tales combinaciones en el tratamiento de condiciones en las que la inhibición de BTK y/o AKT es beneficiosa, por ejemplo, cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461951640P | 2014-03-12 | 2014-03-12 | |
| PCT/IB2015/051380 WO2015136398A1 (en) | 2014-03-12 | 2015-02-24 | Combination comprising a btk inhibitor and an akt inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016011674A true MX2016011674A (es) | 2017-04-27 |
Family
ID=52630445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011674A MX2016011674A (es) | 2014-03-12 | 2015-02-24 | Combinacion que comprende un inhibidor de btk y un inhibidor de akt. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170020878A1 (es) |
| EP (1) | EP3116546A1 (es) |
| JP (1) | JP2017507963A (es) |
| KR (1) | KR20160127754A (es) |
| CN (1) | CN106456642A (es) |
| AU (1) | AU2015228475B9 (es) |
| CA (1) | CA2942204A1 (es) |
| MX (1) | MX2016011674A (es) |
| RU (1) | RU2016139697A (es) |
| WO (1) | WO2015136398A1 (es) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EP2400964A4 (en) * | 2009-01-30 | 2012-08-01 | Glaxosmithkline Llc | CRYSTALLINE FORM OF N - {(1-5) -2-AMINO-1 - [(3-FLUOROPHENYL) METHYL] ETHYL} -5-CHLORO-4- (4-CHLORO-1-METHYL-1H-PYRAZOL) CHLOROHYDRATE 5-YL) -2-THIOPHENE CARBOXAMIDE |
| SG185617A1 (en) | 2010-05-31 | 2012-12-28 | Ono Pharmaceutical Co | Purinone derivative |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| CA2834077A1 (en) | 2011-05-17 | 2012-11-22 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| CA2833771C (en) | 2011-06-10 | 2021-08-03 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| EA201490265A1 (ru) * | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| AU2012285988B2 (en) | 2011-07-19 | 2017-05-25 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides Btk-inhibitors |
| TW201325593A (zh) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法 |
| CA2852964A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Bicyclic piperazine compounds |
| KR102021651B1 (ko) | 2011-11-29 | 2019-09-16 | 오노 야꾸힝 고교 가부시키가이샤 | 퓨리논 유도체 염산염 |
| KR20140131955A (ko) | 2012-03-09 | 2014-11-14 | 카나 바이오사이언스 인코포레이션 | 신규 트리아진 유도체 |
| WO2013161848A1 (ja) | 2012-04-27 | 2013-10-31 | カルナバイオサイエンス株式会社 | 新規１，２，４－トリアジン誘導体 |
| BR112014030424A8 (pt) * | 2012-06-04 | 2017-07-11 | Pharmacyclics Inc | Formas cristalinas de um inibidor de quinase de tirosina de bruton |
| CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
-
2015
- 2015-02-24 CA CA2942204A patent/CA2942204A1/en not_active Abandoned
- 2015-02-24 RU RU2016139697A patent/RU2016139697A/ru not_active Application Discontinuation
- 2015-02-24 JP JP2016556821A patent/JP2017507963A/ja active Pending
- 2015-02-24 AU AU2015228475A patent/AU2015228475B9/en not_active Ceased
- 2015-02-24 WO PCT/IB2015/051380 patent/WO2015136398A1/en active Application Filing
- 2015-02-24 US US15/124,301 patent/US20170020878A1/en not_active Abandoned
- 2015-02-24 KR KR1020167024720A patent/KR20160127754A/ko unknown
- 2015-02-24 CN CN201580013442.2A patent/CN106456642A/zh active Pending
- 2015-02-24 MX MX2016011674A patent/MX2016011674A/es unknown
- 2015-02-24 EP EP15708605.9A patent/EP3116546A1/en not_active Withdrawn
-
2018
- 2018-06-18 US US16/010,945 patent/US20190151319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2942204A1 (en) | 2015-09-17 |
| RU2016139697A (ru) | 2018-04-12 |
| US20170020878A1 (en) | 2017-01-26 |
| KR20160127754A (ko) | 2016-11-04 |
| CN106456642A (zh) | 2017-02-22 |
| RU2016139697A3 (es) | 2018-10-19 |
| AU2015228475A1 (en) | 2016-09-01 |
| JP2017507963A (ja) | 2017-03-23 |
| AU2015228475B9 (en) | 2017-09-21 |
| AU2015228475B2 (en) | 2017-08-17 |
| US20190151319A1 (en) | 2019-05-23 |
| EP3116546A1 (en) | 2017-01-18 |
| WO2015136398A1 (en) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502203A1 (en) | Tyrosine kinase inhibitors | |
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| EA027213B9 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2016010754A (es) | Sales y forma solida de un inhibidor btk. | |
| MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| MY190835A (en) | Bicyclic heterrocyclic derivatives as bromodomain inhibitors | |
| MX2015008196A (es) | Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana. | |
| NZ764150A (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
| MX2017003466A (es) | Inhibidores de histona desmetilasa. | |
| WO2016073771A3 (en) | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors | |
| GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
| MX2016011674A (es) | Combinacion que comprende un inhibidor de btk y un inhibidor de akt. |